Gene · 8764
Papers3,537
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 3,537
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| HtrA3: a promising prognostic biomarker and therapeutic target for head and neck squamous cell carcinoma. | PeerJ | 2023 | 37842043 | PubTator, text mining | PubMed |
| Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index. | Front Immunol | 2023 | 37841237 | PubTator, text mining | PubMed |
| Investigation of LGALS2 expression in the TCGA database reveals its clinical relevance in breast cancer immunotherapy and drug resistance. | Sci Rep | 2023 | 37838802 | PubTator, text mining | PubMed |
| Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer. | NPJ Precis Oncol | 2023 | 37838778 | PubTator, text mining | PubMed |
| Molecular Characterization of Primary Mediastinal Large B-Cell Lymphomas. | Cancers (Basel) | 2023 | 37835560 | PubTator, text mining | PubMed |
| LncRNA RARA-AS1 could serve as a novel prognostic biomarker in pan-cancer and promote proliferation and migration in glioblastoma. | Sci Rep | 2023 | 37833349 | PubTator, text mining | PubMed |
| A seven-immune-genes risk model predicts the survival and suitable treatments for patients with skin cutaneous melanoma. | Heliyon | 2023 | 37809963 | PubTator, text mining | PubMed |
| Novel immune checkpoint-related gene model to predict prognosis and treatment responsiveness in low-grade gliomas. | Heliyon | 2023 | 37809899 | PubTator, text mining | PubMed |
| Patient-derived precision cut tissue slices from primary liver cancer as a potential platform for preclinical drug testing. | EBioMedicine | 2023 | 37806285 | PubTator, text mining | PubMed |
| [Clinical characteristics and efficacy analysis of 11 patients with primary cutaneous diffuse large B-cell lymphoma, leg type]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 37803847 | PubTator, text mining | PubMed |
| Gastric cancer metastasis-related NT5DC2 indicates unfavorable prognosis of patients. | Medicine (Baltimore) | 2023 | 37800836 | PubTator, text mining | PubMed |
| Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists. | Front Immunol | 2023 | 37795079 | PubTator, text mining | PubMed |
| RAD51AP1 as an Immune-Related Prognostic Biomarker and Therapeutic Response Predictor in Hepatocellular Carcinoma. | Int J Gen Med | 2023 | 37789880 | PubTator, text mining | PubMed |
| Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma. | Clin Transl Med | 2023 | 37784253 | PubTator, text mining | PubMed |
| Predictive value of DOT1L mutations for clinical outcomes in non-small-cell lung cancer patients receiving immune checkpoint inhibitor therapy. | Clin Transl Med | 2023 | 37784247 | PubTator, text mining | PubMed |
| Comprehensive analysis of Cuproplasia and immune microenvironment in lung adenocarcinoma. | Front Pharmacol | 2023 | 37781711 | PubTator, text mining | PubMed |
| Identification of novel lactate metabolism-related lncRNAs with prognostic value for bladder cancer. | Front Pharmacol | 2023 | 37781694 | PubTator, text mining | PubMed |
| Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal Cell Carcinoma with Distinct Prognosis and Tumor Microenvironment Characteristics. | Int J Biol Sci | 2023 | 37781030 | PubTator, text mining | PubMed |
| Endogenous retrovirus group FRD member 1 is a potential biomarker for prognosis and immunotherapy for kidney renal clear cell carcinoma. | Front Cell Infect Microbiol | 2023 | 37780849 | PubTator, text mining | PubMed |
| Laminin 332 expression levels predict clinical outcomes and chemotherapy response in patients with pancreatic adenocarcinoma. | Front Cell Dev Biol | 2023 | 37779898 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8764/papers?page=19